AMND2017

Document PDF Download program in PDF document

Sunday, October 22, 2017

Arrival
Shuttle from Prague Airport to Chateau Liblice will be provided.

Registration, Welcome Drink

Monday, October 23, 2017

Opening of the Conference

Keynote Lecture

8.30 - 9.10
Petr Svoboda, Prague, Czech Republic - A sobering look at the mammalian RNAi pathway

Session 1

Perspectives from Rodent Models for Neurodegenerative Diseases

9.10 - 9.50
Slaven Erzeg, Valencia, Spain - Induced pluripotent stem cells for modelling and treatment of human neurodegenerative diseases

9.50 - 10.20
Marian Hruska-Plochan, Zurich, Switzerland - Interaction of DPRs alter their subcellular localization, aggregation pattern (and toxicity)

10.20 - 10.50
Martin Balaštík, Praha, Czech Republic - Isomerase Pin1 as a regulator of stability and solubility of CRMP2 in aging and AD.

11.20 - 11.50
Huu Phuc Nhuyen, Tuebingen, Germany - Effects of lowering huntingtin in the Hypothalamus in the BACHD rat

11.50 - 12.20
Petr Vodicka, Boston, USA / Libechov, Czech Republic – Stimulating autophagy and reducing inclusions in mouse model of Huntington's disease via expression of transcription factor EB (TFEB)

12.20 - 12.50
Helena Skalnikova, Libechov, Czech Republic - Exosomes as potential carriers of biomarkers in neurodegenerative diseases

12.50 - 13.20
Marta Biagioli, Italy - Aberrant Alternative Splicing as a new player in Huntington’s Disease pathogenesis

HD and ALS – Clinical view:

14.30 - 15.00
Jiri Klempir, Prague, Czech Republic – Living with neurodegeneration

Session 2

Progress in Technologies and Development of Large Animal Models of HD and ALS

15.00 – 15.30
Carsten Bjarkam Alborg, DK - Cytoarchitecture and surface anatomy of the Göttingen minipig telencephalon

15.30 - 16.00
Owen Lewis, Bristol, UK - Functional and translational performance of a novel recessed-step catheter and stereotactic system for use in pre-clinical and clinical CED indications

16:00 – 16:30
Bas Blits, Amsterdam, NL - AAV mediated delivery in large animals

16.30 – 17:00
Martin Marsala, San Diego, USA - Potent anti-spasticity and anti-nociceptive effect of subpial GAD65 and VGAT delivery in rat and mice

Video conference

17.30 – 18.30
Gene W. Yeo, San Diego, USA - RNA targeting CRISPR technologies for disease applications

Concert and dance

Tuesday, October 24, 2017

Session 3

Perspectives of Gene Therapy in Neurodegenerative Diseases

8.30 – 9.00
Nik Klymiuk, Munich, Germany - Gene Editing for Tailoring Pig Models for Monogenic Diseases

9.00 – 9.30
Melvin Evers, Amsterdam, NL - Establishing proof-of-concept of gene therapy for Huntington’s disease

9.30 – 10.00
Edith L. Pfister, Boston, USA – Reduction of Huntingtin by an scAAV9 artificial miRNA in large animals

10.00 – 10.20
Petra Vochozkova, Munich, Germany / Libechov, Czech Republic - Evaluation of strategies for humanization of the entire porcine HTT locus.

Session 4

New DNA Damage and Mitochondria Biomarkers in Development of HD and ALS

13.00 -13.30
Lars Eide, Oslo, Norway - New DNA Damage and Mitochondria Biomarkers in Development of HD and ALS.

13.30 – 14.00
Hana Hansikova, Prague, Czech Republic - Mitochondrial phenotype in minipig model transgenic for N-terminal part of human mutated huntingtin

14.00 – 14.20
Petra Šmatlíková, Libechov, Czech Republic - Oxidative stress in Primary Porcine Fibroblasts Expressing Mutated Huntingtin.

14.20 – 14.50
Petr Šolc, Libechov, Czech Republic - DNA damage response in the development of Huntington´s disease

14.50 – 15.10
Michaela Vaškovičová, Libechov, Czech Republic - Double strand DNA breaks response in Huntington´s disease transgenic minipigs

Session 5

Development of New Cognitive and Behavioral Tests in Large Animal Models of HD

15.40 – 16.10
Zdenka Ellederova, Libechov, Czech Republic - Following the phenotype development of TgHD minipigs by invasive and noninvasive approach.

16.10 – 16.40
Verena Schuldenzucker, Muenster, Germany - Longitudinal phenotyping of tgHD minipigs

16.40 -17.10
Ralf Reilmann, Muenster, Germany - The minipig model in Huntington Disease - opportunities and challenges